Pee and Period Proof Underwear and Nursing Pads Revenue and Competitors

Location

N/A

Total Funding

Apparel

Industry

Estimated Revenue & Valuation

  • Pee and Period Proof Underwear and Nursing Pads's estimated annual revenue is currently $2.3M per year.(i)
  • Pee and Period Proof Underwear and Nursing Pads's estimated revenue per employee is $155,040

Employee Data

  • Pee and Period Proof Underwear and Nursing Pads has 15 Employees.(i)
  • Pee and Period Proof Underwear and Nursing Pads grew their employee count by 15% last year.

Pee and Period Proof Underwear and Nursing Pads's People

NameTitleEmail/Phone
1
Founder and Design DirectorReveal Email/Phone
2
CFOReveal Email/Phone
3
VP I Sales & Marketing HeadReveal Email/Phone
4
Operations ManagerReveal Email/Phone
5
Digital / e-commerce ManagerReveal Email/Phone
6
Product Development ManagerReveal Email/Phone
7
Project ManagerReveal Email/Phone
8
Marketing ExecutiveReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$68.7M28836%N/AN/A
#2
$12.1M610%$16.7MN/A
#3
$13M0N/A$13.5MN/A
#4
$19.8M876%N/AN/A
#5
$168.7M59211%N/AN/A
#6
$12.7M516%N/AN/A
#7
$5.5M3011%N/AN/A
#8
$26.7M11722%N/AN/A
#9
$23.7M823%N/AN/A
#10
$168.7M4765%N/AN/A
Add Company

What Is Pee and Period Proof Underwear and Nursing Pads?

keywords:N/A

N/A

Total Funding

15

Number of Employees

$2.3M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pee and Period Proof Underwear and Nursing Pads News

2022-04-17 - Need to pee' pill for overactive bladder could be sold over the counter

One in six women in the UK suffer with symptoms related to an overactive bladder.

2022-04-17 - Pill to control ‘sudden urge to pee’ could be sold over the counter in UK

Millions of women suffering from an overactive bladder have been urged to take part in a consultation that could make a treatment available...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.2M15-32%N/A
#2
$0.9M1515%$200M
#3
$0.6M150%$4.3M
#4
$3.7M15-12%N/A
#5
$1.3M15N/AN/A